Free Trial

Diversified Trust Co Boosts Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Ascendis Pharma A/S logo with Medical background

Diversified Trust Co increased its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,548 shares of the biotechnology company's stock after acquiring an additional 1,510 shares during the quarter. Diversified Trust Co owned 0.08% of Ascendis Pharma A/S worth $7,255,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Ascendis Pharma A/S in the 4th quarter valued at about $28,000. Jones Financial Companies Lllp grew its stake in Ascendis Pharma A/S by 394.0% in the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 197 shares during the period. Quarry LP bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter valued at approximately $96,000. Tower Research Capital LLC TRC raised its position in shares of Ascendis Pharma A/S by 195.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after purchasing an additional 664 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in shares of Ascendis Pharma A/S in the 4th quarter worth $174,000.

Ascendis Pharma A/S Stock Down 0.7%

ASND stock traded down $1.25 during midday trading on Monday, hitting $170.97. The company's stock had a trading volume of 327,224 shares, compared to its average volume of 497,238. The stock has a market cap of $10.45 billion, a price-to-earnings ratio of -27.22 and a beta of 0.37. The stock's 50-day moving average price is $166.42 and its 200 day moving average price is $151.06. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. As a group, equities analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on ASND. Morgan Stanley upgraded shares of Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $180.00 to $250.00 in a research note on Monday, May 5th. JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a report on Friday, May 2nd. Cantor Fitzgerald restated an "overweight" rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a report on Monday, May 12th. Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Finally, Oppenheimer reissued an "outperform" rating and set a $224.00 price objective (up from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $220.67.

Get Our Latest Research Report on Ascendis Pharma A/S

Ascendis Pharma A/S Profile

(Free Report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

See Also

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Should You Invest $1,000 in Ascendis Pharma A/S Right Now?

Before you consider Ascendis Pharma A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.

While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines